Aggregated News
Several biotech companies and business groups have lodged formal objections to the policy, tentatively adopted in February by the California Institute for Regenerative Medicine, which oversees the stem-cell research effort created in 2004 by Proposition 71.
``These provisions substantially reduce or eliminate the incentives to commercialize patented stem cell-related technologies and products even in spite of the generous funding provided by Proposition 71,'' the Washington-based Biotech Industry Organization complained in a letter to the institute.
In addition, the California Healthcare Institute, which represents biotech firms across the state, warned that deterring companies from participating in stem-cell research could have dire consequences for people suffering from a variety of ailments.
``Without private sector investment in research innovations, stem cell research and the development of resulting new treatments and therapies will be constrained,'' it said.
The comments, which were...